Mankind Pharma Ltd
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
- Market Cap ₹ 1,00,040 Cr.
- Current Price ₹ 2,425
- High / Low ₹ 3,055 / 1,901
- Stock P/E 49.0
- Book Value ₹ 256
- Dividend Yield 0.00 %
- ROCE 26.2 %
- ROE 21.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 9.47 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.16%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Dollex 200 BSE Allcap BSE 200 Nifty 500 BSE 100 LargeCap TMC Index
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|
| 3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 10,335 | 11,641 | |
| 2,748 | 4,427 | 4,565 | 5,791 | 6,848 | 7,796 | 8,688 | |
| Operating Profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,538 | 2,953 |
| OPM % | 18% | 25% | 27% | 26% | 22% | 25% | 25% |
| 76 | 122 | 183 | 210 | 141 | 294 | 392 | |
| Interest | 2 | 23 | 21 | 60 | 46 | 35 | 248 |
| Depreciation | 39 | 99 | 119 | 167 | 326 | 398 | 510 |
| Profit before tax | 621 | 1,438 | 1,692 | 1,975 | 1,671 | 2,399 | 2,586 |
| Tax % | 29% | 27% | 24% | 26% | 22% | 19% | |
| 445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,942 | 2,063 | |
| EPS in Rs | 219.33 | 25.72 | 31.59 | 35.78 | 32.00 | 47.75 | 50.68 |
| Dividend Payout % | 0% | 0% | 24% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| Last Year: | 22% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 | 40 |
| Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 9,323 | 10,525 |
| 0 | 131 | 241 | 873 | 170 | 207 | 482 | |
| 968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,313 | 2,935 | |
| Total Liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 13,982 |
| 316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,545 | 4,561 | |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 224 |
| Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,568 | 3,856 |
| 1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,488 | 5,340 | |
| Total Assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 13,982 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 1,070 | 1,137 | 920 | 1,813 | 2,152 | ||
| -436 | -1,222 | -1,369 | -1,052 | -2,081 | ||
| -531 | -8 | 605 | -740 | 5 | ||
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 22 | 33 | 19 | 18 | 24 | 30 |
| Inventory Days | 166 | 175 | 243 | 265 | 188 | 179 |
| Days Payable | 71 | 145 | 137 | 162 | 126 | 127 |
| Cash Conversion Cycle | 117 | 63 | 125 | 121 | 86 | 82 |
| Working Capital Days | 56 | 35 | 43 | 62 | 45 | 41 |
| ROCE % | 37% | 32% | 22% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
1m - Increase in Authorized Share Capital of the Company pursuant to effect of the Scheme of arrangement of amalgamation amongst Shree Jee Laboratory Private Limited, JPR …
-
Effective Date Of The Scheme Of Arrangement For Amalgamation Amongst Shree Jee Laboratory Private Limited , JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma Limited
10m - Amalgamation of Shree Jee Laboratory and others with Mankind Pharma.
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
18h - NCLT approves amalgamation of BSV Pharma with Bharat Serums.
-
Intimation Under Regulation 30 Of The SEBI (LODR), Regulations, 2015
18h - Company received tax assessment orders for AY 2014-15 to 2017-18.
-
Closure of Trading Window
2d - Closure of trading window until financial results announcement.
Concalls
-
Jan 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Sep 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jul 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
Leadership[1]
- 1 Rank in Prescriptions over the last 5 yrs.
- Youngest in the Top 5 of the IPM
- 4 By value in the IPM
- 4 Consumer Healthcare brands Market ranked
1 in their categories